Dosing & Uses
B-Cell Lymphoma
Pending FDA approval for relapsed/refractory large B-cell lymphoma (LBCL) after ≥2 lines of systemic therapy
Next:
Pharmacology
Mechanism of Action
Bispecific antibody designed to simultaneously bind to CD3 on T-cells and CD20 on B-cells, and induces T-cell mediated killing of CD20+ cells
CD20 is expressed on B-cells and a clinically validated therapeutic target in many B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
